<?xml version='1.0' encoding='utf-8'?>
<document id="27862160"><sentence text="In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin."><entity charOffset="106-119" id="DDI-PubMed.27862160.s1.e0" text="canagliflozin" /></sentence><sentence text="Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes"><entity charOffset="0-13" id="DDI-PubMed.27862160.s2.e0" text="Canagliflozin" /></sentence><sentence text=" The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed"><entity charOffset="19-32" id="DDI-PubMed.27862160.s3.e0" text="canagliflozin" /></sentence><sentence text="" /><sentence text="DDI potential of canagliflozin was investigated using in vitro test systems containing drug metabolizing enzymes or transporters"><entity charOffset="17-30" id="DDI-PubMed.27862160.s5.e0" text="canagliflozin" /></sentence><sentence text=" Basic predictive approaches were applied to determine potential interactions in vivo" /><sentence text=" A physiologically-based pharmacokinetic (PBPK) model was developed and clinical DDI simulations were performed to determine the likelihood of cytochrome P450 (CYP) inhibition by canagliflozin"><entity charOffset="179-192" id="DDI-PubMed.27862160.s7.e0" text="canagliflozin" /></sentence><sentence text="" /><sentence text="Canagliflozin was primarily metabolized by uridine 5'-diphospho-glucuronosyltransferase 1A9 and 2B4 enzymes"><entity charOffset="0-13" id="DDI-PubMed.27862160.s9.e0" text="Canagliflozin" /></sentence><sentence text=" Canagliflozin was a substrate of efflux transporters (P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein-2) but was not a substrate of uptake transporters (organic anion transporter polypeptide isoforms OATP1B1, OATP1B3, organic anion transporters OAT1 and OAT3, and organic cationic transporters OCT1, and OCT2)"><entity charOffset="1-14" id="DDI-PubMed.27862160.s10.e0" text="Canagliflozin" /></sentence><sentence text=" In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4"><entity charOffset="23-36" id="DDI-PubMed.27862160.s11.e0" text="canagliflozin" /></sentence><sentence text="9), CYP2C9 (80 μmol l -1 , SE 8" /><sentence text="1), CYP2B6 (16 μmol l-1 , SE 2" /><sentence text="1), CYP2C8 (75 μmol l -1 , SE 6" /><sentence text="4), P-glycoprotein (19" /><sentence text="3 μmol l -1 , SE 7" /><sentence text="2), and multidrug resistance-associated protein-2 (21" /><sentence text="5 μmol l -1 , SE 3" /><sentence text="1)" /><sentence text=" Basic models recommended in DDI guidelines (US Food &amp; Drug Administration and European Medicines Agency) predicted moderate to low likelihood of interaction for these CYPs and efflux transporters" /><sentence text=" PBPK DDI simulations of canagliflozin with CYP probe substrates (simvastatin, S-warfarin, bupropion, repaglinide) did not show relevant interaction in humans since mean areas under the concentration-time curve and maximum plasma concentration ratios for probe substrates with and without canagliflozin and its 95% CIs were within 0"><entity charOffset="25-38" id="DDI-PubMed.27862160.s21.e0" text="canagliflozin" /><entity charOffset="66-77" id="DDI-PubMed.27862160.s21.e1" text="simvastatin" /><entity charOffset="79-89" id="DDI-PubMed.27862160.s21.e2" text="S-warfarin" /><entity charOffset="91-100" id="DDI-PubMed.27862160.s21.e3" text="bupropion" /><entity charOffset="102-113" id="DDI-PubMed.27862160.s21.e4" text="repaglinide" /><entity charOffset="289-302" id="DDI-PubMed.27862160.s21.e5" text="canagliflozin" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e0" e2="DDI-PubMed.27862160.s21.e0" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e0" e2="DDI-PubMed.27862160.s21.e1" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e0" e2="DDI-PubMed.27862160.s21.e2" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e0" e2="DDI-PubMed.27862160.s21.e3" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e0" e2="DDI-PubMed.27862160.s21.e4" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e0" e2="DDI-PubMed.27862160.s21.e5" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e1" e2="DDI-PubMed.27862160.s21.e1" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e1" e2="DDI-PubMed.27862160.s21.e2" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e1" e2="DDI-PubMed.27862160.s21.e3" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e1" e2="DDI-PubMed.27862160.s21.e4" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e1" e2="DDI-PubMed.27862160.s21.e5" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e2" e2="DDI-PubMed.27862160.s21.e2" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e2" e2="DDI-PubMed.27862160.s21.e3" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e2" e2="DDI-PubMed.27862160.s21.e4" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e2" e2="DDI-PubMed.27862160.s21.e5" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e3" e2="DDI-PubMed.27862160.s21.e3" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e3" e2="DDI-PubMed.27862160.s21.e4" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e3" e2="DDI-PubMed.27862160.s21.e5" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e4" e2="DDI-PubMed.27862160.s21.e4" /><pair ddi="false" e1="DDI-PubMed.27862160.s21.e4" e2="DDI-PubMed.27862160.s21.e5" /></sentence><sentence text="80-1" /><sentence text="25" /><sentence text="" /><sentence text="In vitro DDI followed by a predictive or PBPK approach was applied to determine DDI potential of canagliflozin"><entity charOffset="97-110" id="DDI-PubMed.27862160.s25.e0" text="canagliflozin" /></sentence><sentence text=" Overall, canagliflozin is neither a perpetrator nor a victim of clinically important interactions"><entity charOffset="10-23" id="DDI-PubMed.27862160.s26.e0" text="canagliflozin" /></sentence><sentence text="" /></document>